Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis.

Jacobs JW.

Rheumatology (Oxford). 2012 Jun;51 Suppl 4:iv3-8. doi: 10.1093/rheumatology/kes083. Epub 2012 Apr 19. Review.

PMID:
22513146
2.

Remission in rheumatoid arthritis: wishful thinking or clinical reality?

Sesin CA, Bingham CO 3rd.

Semin Arthritis Rheum. 2005 Dec;35(3):185-96.

PMID:
16325659
3.

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.

Gaujoux-Viala C, Nam J, Ramiro S, Landewé R, Buch MH, Smolen JS, Gossec L.

Ann Rheum Dis. 2014 Mar;73(3):510-5. doi: 10.1136/annrheumdis-2013-204588. Epub 2014 Jan 6. Review.

4.

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.

Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.

Ann Rheum Dis. 2015 Jan;74(1):27-34. doi: 10.1136/annrheumdis-2014-205489. Epub 2014 Oct 30.

PMID:
25359382
5.

Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.

Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.

Ann Rheum Dis. 2017 Mar;76(3):511-520. doi: 10.1136/annrheumdis-2016-209212. Epub 2016 Jul 18.

PMID:
27432356
6.

Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.

Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangier-de Veen ZN, van der Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW; Utrecht Rheumatoid Arthritis Cohort Study Group.

Ann Intern Med. 2012 Mar 6;156(5):329-39. doi: 10.7326/0003-4819-156-5-201203060-00004.

PMID:
22393128
7.

Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.

Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.

Semin Arthritis Rheum. 2007 Oct;37(2):99-111. Epub 2007 Mar 27.

PMID:
17391739
8.

Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies.

Jacobs JW.

Rheumatology (Oxford). 2012 Jun;51 Suppl 4:iv27-33. doi: 10.1093/rheumatology/kes084. Review.

PMID:
22685273
9.

The use of conventional disease-modifying anti-rheumatic drugs in established RA.

Jurgens MS, Jacobs JW, Bijlsma JW.

Best Pract Res Clin Rheumatol. 2011 Aug;25(4):523-33. doi: 10.1016/j.berh.2011.10.006. Review.

PMID:
22137922
11.

The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.

Aletaha D, Smolen JS.

Rheumatology (Oxford). 2002 Dec;41(12):1367-74.

PMID:
12468815
12.

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM, Scholte-Voshaar M, van Riel P, Gossec L.

Ann Rheum Dis. 2010 Jun;69(6):1004-9. doi: 10.1136/ard.2009.127225. Epub 2010 May 6. Review.

PMID:
20447954
13.

The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy.

Kissin EY.

Clin Ther. 2014 Jul 1;36(7):1114-6. doi: 10.1016/j.clinthera.2014.06.012. Epub 2014 Jul 2.

PMID:
24996488
14.

The methotrexate therapeutic response in rheumatoid arthritis.

Ortendahl M, Holmes T, Schettler JD, Fries JF.

J Rheumatol. 2002 Oct;29(10):2084-91.

PMID:
12375316
15.
16.

Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.

Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.

Scand J Rheumatol. 2009;38(5):323-7. doi: 10.1080/03009740902946355.

PMID:
19585384
17.

A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.

Ma MH, Kingsley GH, Scott DL.

Rheumatology (Oxford). 2010 Jan;49(1):91-8. doi: 10.1093/rheumatology/kep331. Epub 2009 Nov 16. Review.

PMID:
19917618
18.

Developing an effective treatment algorithm for rheumatoid arthritis.

Keystone EC, Smolen J, van Riel P.

Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v48-54. doi: 10.1093/rheumatology/kes122. Review.

PMID:
22718927
19.

Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.

Fautrel B, Guillemin F, Meyer O, de Bandt M, Berthelot JM, Flipo RM, Lioté F, Maillefert JF, Wendling D, Saraux A, Combe B, Le Loët X; Stratégies Thérapeutiques dans La Polyarthrite RhumatoIde Working Group; Club Rhumatismes et Inflammation; French Society of Rheumatology.

Arthritis Rheum. 2009 Apr 15;61(4):425-34. doi: 10.1002/art.24588.

Supplemental Content

Support Center